Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION

Overview of attention for article published in Trials, August 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter: 3 tweeters

Readers on

mendeley: 11 Mendeley

Summary Twitter

So far, Altmetric has seen 3 tweets from 3 users, with an upper bound of 767 followers.

Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION https://t.co/6upRr8b6oG

13 Sep 2022

Reply Retweet Favourite

BIG NEWS! We are delighted to announce the #studyprotocol for our #IXION #clinicaltrial has been published in TRIALS @BioMedCentral ! To learn more, click the link👉https://t.co/vNRM49byYT #euproject #covid19research #covid19solutions #clinicaltrial #biot

24 Aug 2022

Reply Retweet Favourite

Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients - the randomized, EU-wide, placebo-controlled, phase II study design of IXION https://t.co/eVeIlwGT4D

20 Aug 2022

Reply Retweet Favourite

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity.